Marco High-Cost Drugs integrates a specialized database on rare diseases and high-cost drugs, enabling hospital medical teams to access updated information on available therapeutic options, clinical evidence, and eligibility criteria for their patients.
Some answers to questions we often receive
The database includes high-cost drug profiles with FDA/EMA-approved indications, eligibility criteria, available clinical evidence, regulatory status by country, and expanded or compassionate access options.
The database is updated continuously with approvals from FDA, EMA, ANVISA, and other relevant regulatory bodies, as well as new clinical evidence publications.
Yes. Marco includes detailed information on the processes and requirements for accessing compassionate use and expanded access programs by manufacturer and country, facilitating the hospital's administrative management of these cases.
Yes. Marco High-Cost Drugs includes information on active clinical trials with patient access, expanded access programs, and drugs undergoing regulatory approval.
Yes. The database includes the regulatory approval status in the main Latin American countries: ANVISA (Brazil), ISP (Chile), ANMAT (Argentina), and COFEPRIS (Mexico), in addition to FDA and EMA approvals.
Yes. Marco can generate structured evidence summaries for a specific drug and indication, usable as the basis for exceptional coverage request reports submitted to insurers or public health funds.
Hospitals treat patients with rare diseases and difficult-to-treat tumors and need updated information on high-cost drugs, eligibility criteria, and access to innovative therapies.
